This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Forst, T. Articles by Hanefeld, M. Search for Related Content PubMed PubMed Citation Articles by Forst, T. Articles by Hanefeld, M. Social Bookmarking                         What's this?

Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk

Institute for Clinical Research and Development, Mainz, Germany.

Birgit Wilhelm

Institute for Clinical Research and Development, Mainz, Germany.

Andreas Pfützner

Institute for Clinical Research and Development, Mainz, Germany.

Winfried Fuchs

Takeda Pharma GmbH, Aachen, Germany.

Ute Lehmann

Takeda Pharma GmbH, Aachen, Germany.

Frank Schaper

GWT-TUD, Dresden, Germany.

Matthias Weber

Johannes Gutenberg University, Department of Endocrinology, Mainz, Germany.

Jürgen Müller

Acromion, Frechen, Germany.

Thomas Konrad

Institute for Metabolic Research, Frankfurt, Germany.

Markolf Hanefeld

GWT-TUD, Dresden, Germany.

We investigated the effect of atorvastatin monotherapy and combined treatment with atorvastatin and pioglitazone on intima-media thickness, vascular function and the cardiovascular risk profile. In all, 148 patients (76 male, 72 female; aged 61.4±6.5 years; body mass index [BMI] 29.2±4.1 kg/m²; mean±SD) with increased cardiovascular (CV) risk factors were randomised. Intima-media thickness (IMT), the augmentation index (Aix@75), the microvascular response to acetylcholine (LDF), lipid status, and plasma levels of intact proinsulin, adiponectin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), sCD40L, P-selectin, tissue plasminogen activator (t-PA) and blood lipids were monitored over six months.

Atorvastatin treatment, alone and in combination with pioglitazone, revealed a significant regression in IMT (0.923±0.013 to 0.874±0.012 mm and 0.921±0.015 to 0.882±0.015 mm; mean ± SEM; p<0.05 respectively) and Aix@75 (27.3±1.2 to 25.9±1.4; and 25.6±1.4 to 24.8±1.7%; p<0.05). The endothelial response to acetylcholine as measured by laser Doppler fluximetry (LDF) improved during combined treatment (373±57 to 576±153 AU; p<0.05). Addition of pioglitazone to atorvastatin resulted in significant further effects on high-sensitivity C-reactive protein (hsCRP), t-PA, P-selectin, adiponectin, triglycerides and high-density lipoprotein (HDL) cholesterol (p<0.05 respectively).

Atorvastatin significantly improved IMT and vascular elasticity. Co-administration of pioglitazone provided additional effects on endothelial function, lipid profile and laboratory markers of inflammation.

Key Words: atherosclerosis • inflammation • intima-media thickness • PPAR • statins.

Diabetes and Vascular Disease Research, Vol. 5, No. 4, 298-303 (2008)
DOI: 10.3132/dvdr.2008.043


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?